Adrian Rawcliffe, Chief Executive Officer at Adaptimmune Therapeutics PLC (ADAP), sold 29,202 shares at $0.84 ($25K) on 2024-01-11, disclosed to the SEC on 2024-01-12.
Seasonal sale ($25k) by Chief Executive Officer — this insider has traded ADAP in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.84 | 11,945 | $10K | 40.6% |
| 2 | $0.85 | 17,257 | $15K | 59.4% |
| Total | $0.85 avg | 29,202 | $25K | 100% |
| Filing → |
| WVE | SELL | 2025-11-14 | $219K | — | Filing → |
| ADAP | SELL | 2025-01-17 | $18K | — | Filing → |
| ADAP | SELL | 2025-01-15 | $35K | — | Filing → |